ABSTRACT
Objective To evaluate in vivo the co-occurrence of microglial activation and microstructural white matter damage in multiple sclerosis (MS) brain, and to examine their association with clinical disability.
Methods 18-kDa translocator protein (TSPO) brain PET imaging was performed for evaluation of microglial activation by using the radioligand [11C](R)-PK11195. TSPO-binding was evaluated as the distribution volume ratio (DVR) from dynamic PET images. Diffusion tensor imaging (DTI) and conventional MRI were performed at the same time. Mean fractional anisotropy (FA) and mean (MD), axial (AD) and radial (RD) diffusivities were calculated within the whole normal appearing white matter (NAWM) and segmented NAWM regions appearing normal in conventional MRI. 55 MS patients and 15 healthy controls were examined.
Results Microstructural damage was observed in the NAWM of MS brain. DTI parameters of MS patients were significantly altered in the NAWM, when compared to an age- and sex-matched healthy control group: mean FA was decreased, and MD, AD and RD were increased. These structural abnormalities correlated with increased TSPO binding in the whole NAWM and in the temporal NAWM (p<0.05 for all correlations; p<0.01 for RD in the temporal NAWM). Both compromised WM integrity and increased microglial activation in the NAWM correlated significantly with higher clinical disability measured with expanded disability status scale (EDSS).
Conclusions Widespread structural disruption in the NAWM is linked to neuroinflammation, and both phenomena associate with clinical disability. Multimodal PET and DTI imaging allows in vivo evaluation of widespread MS pathology not visible using conventional MRI.
Supplemental data: Table e-1. Clinical and conventional MRI parameters of healthy controls and multiple sclerosis patients
Table e-2. The effect of number of gradients (64 vs. 33) on DTI-derived measures
Table e-3. Associations of DTI and TSPO-PET measures in the segmented NAWM with disability and disease severity among MS patients (n=55).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for this study was provided by the Finnish Academy, the Sigrid Juselius Foundation and The Finnish MS Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
First author: Svetlana Bezukladova, Turku PET Centre, Turku University Hospital, P.O. Box 52, 20521 Turku, Finland. Neuroimmunology Unit, Division of Neuroscience, Institute of Experimental Neurology, IRCCS San Raffaele Hospital, Via Olgettina 58, 20132, Milan, Italy. Phone: +390226434854; Fax: +390226434855. E-mail: bezukladova.svetlana{at}hsr.it
Financial Disclosures: Financial support for this study was provided by the Finnish Academy, the Sigrid Juselius Foundation and The Finnish MS Foundation.
Svetlana Bezukladova – Reports no disclosures
Jouni Tuisku was supported by the Alfred Kordelin Foundation, Instrumentarium Science Foundation, Orion Research Foundation, Paulo Foundation, Päivikki and Sakari Sohlberg Foundation and Turku University Hospital Foundation.
Markus Matilainen - Reports no disclosures
Anna Vuorimaa - Reports no disclosures
Marjo Nylund - Reports no disclosures
Sarah Smith - Reports no disclosures
Marcus Sucksdorff has received personal research grants from the Finnish MS Foundation and the Finnish Medical Foundation
Mehrbod Mohammadian - Reports no disclosures
Virva Saunavaara - Reports no disclosures
Sini Laaksonen - Reports no disclosures
Johanna Rokka has received personal research grant from Sigrid Juselius Foundation
Juha O. Rinne has received research grants from the Academy of Finland, the Sigrid Juselius Foundation, the Finnish National Neurocenter and Governmental Research Grants (VTR)
Eero Rissanen has received speaker honoraria from Teva, Biogen, and Roche, a consultational fee for Merck and personal research grants from Turku University Hospital (State Research Funding) and the Finnish MS Foundation.
Laura Airas has received research grants from Academy of Finland, the Sigrid Juselius Foundation, the Finnish National Neurocenter and Governmental Research Grants (VTR), institutional research grant support from Genzyme, and honoraria from Biogen, F. Hoffmann-La Roche Ltd, Genzyme and MerckSerono.
Statistical Analysis conducted by Dr. Matilainen, PhD, Ms. Bezukladova, MSc and Mr. Tuisku, MSc from Turku PET Centre, Turku University Hospital and University of Turku.
Data Availability
The raw data used in the preparation of this article can be shared in anonymized format by request of a qualified investigator.
